Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma

Authors

Xianggui Yuan,† Yaping Xie,† Nengwen Xu,† Hui Liu,‡ Panpan Chen,† Aiqi Zhao,† Yun Liang† and Wenbin Qian†,‡

†Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou; ‡Department of Hematology, the Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou; §Department of Hematology, the Lishui Hospital, Zhejiang University School of Medicine, Lishui and ¶National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China

†XY, YX and NX contributed equally as first authors.

Correspondence:
W.-B. QIAN – qianwb@zju.edu.cn
Y. LIANG – liangyun@zju.edu.cn

https://doi.org/10.3324/haematol.2023.284834
Supplementary material

20 patients assessed for eligibility

1 patient withdrew before treatment; 2 patient did not meet inclusion criteria

17 enrolled and received induction therapy

2 PD withdrew

15 received 4 cycles of induction therapy

<PR

0 withdrew

≥ PR

15 completed 6 cycles of induction therapy

1 PD withdrew

<CR

2 salvage WBRT

CR

14 received maintenance therapy

1 CR

2 PD withdrew

12 completed maintenance therapy

Supplementary Figure S1. Study flow diagram
Supplementary Figure S2. Survival curves.

(A) Subgroup analysis of PFS based on International Extranodal Lymphoma Study Group (IELSG) risk stratification. (B) Subgroup analysis of OS based on IELSG risk stratification. (C) Subgroup analysis of PFS based on Memorial Sloan-Kettering Cancer Center (MSKCC) risk stratification. (D) Subgroup analysis of OS based on MSKCC risk stratification.